Rigel Pharmaceuticals (RIGL) Cash from Operations (2010 - 2026)
Rigel Pharmaceuticals' quarterly Cash from Operations came in at 2725000.0 in Q1 2026, up 405.15% year-on-year from 539442.47 in Q1 2025, and down 87.6% quarter-over-quarter from 21980000.0 in Q4 2025.
Rigel Pharmaceuticals has reported Cash from Operations for 17 years, with the latest figure at 2725000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations rose 405.15% year-over-year to 2725000.0; the trailing twelve-month figure through Mar 2026 stood at 79273000.0 (up 122.73% YoY), and the FY2025 full-year result was 75655000.0, up 140.4% from the prior year.
- Cash from Operations for Q1 2026 stood at 2725000.0, down from 21980000.0 in the prior quarter.
- The five-year high for Cash from Operations was 30537000.0 in Q2 2025, with the low at 25637000.0 in Q1 2022.
- Average Cash from Operations over 5 years is 1785294.12, with a median of 893000.0 recorded in 2025.
- Year-over-year, Cash from Operations sank 123.38% in 2022 and surged 10011.59% in 2025.
- Tracing RIGL's Cash from Operations over 5 years: stood at 21909000.0 in 2022, then soared by 71.52% to 6240000.0 in 2023, then jumped by 332.42% to 14503000.0 in 2024, then surged by 51.55% to 21980000.0 in 2025, then tumbled by 87.6% to 2725000.0 in 2026.
- The last three Cash from Operations figures came in at 2725000.0 (Q1 2026), 21980000.0 (Q4 2025), and 24031000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.08 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.50 Mn |
| 10 | Rigel Pharmaceuticals | 551.62 Mn | 404.94 Mn | 54.21 Mn | 2.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.73 Mn |
| Mar 31, 2026 | 2.73 Mn |
| Dec 31, 2025 | 21.98 Mn |
| Dec 31, 2025 | 21.98 Mn |
| Sep 30, 2025 | 24.03 Mn |
| Sep 30, 2025 | 24.03 Mn |
| Jun 30, 2025 | 30.54 Mn |
| Jun 30, 2025 | 30.54 Mn |
| Mar 31, 2025 | -893,000.00 |
| Mar 31, 2025 | -893,000.00 |
| Dec 31, 2024 | 14.50 Mn |
| Dec 31, 2024 | 14.50 Mn |
| Sep 30, 2024 | 21.68 Mn |
| Sep 30, 2024 | 21.68 Mn |
| Jun 30, 2024 | 302,000.00 |
| Jun 30, 2024 | 302,000.00 |
| Mar 31, 2024 | -5.01 Mn |
| Mar 31, 2024 | -5.01 Mn |
| Dec 31, 2023 | -6.24 Mn |
| Dec 31, 2023 | -6.24 Mn |
| Sep 30, 2023 | -1.36 Mn |
| Sep 30, 2023 | -1.36 Mn |
| Jun 30, 2023 | 5.93 Mn |
| Jun 30, 2023 | 5.93 Mn |
| Mar 31, 2023 | -4.07 Mn |
| Mar 31, 2023 | -4.07 Mn |
| Dec 31, 2022 | -21.91 Mn |
| Dec 31, 2022 | -21.91 Mn |
| Sep 30, 2022 | -13.30 Mn |
| Sep 30, 2022 | -13.30 Mn |
| Jun 30, 2022 | -12.91 Mn |
| Jun 30, 2022 | -12.91 Mn |
| Mar 31, 2022 | -25.64 Mn |
| Mar 31, 2022 | -25.64 Mn |
| Dec 31, 2021 | -19.09 Mn |
| Dec 31, 2021 | -19.09 Mn |
| Sep 30, 2021 | -10.30 Mn |
| Sep 30, 2021 | -10.30 Mn |
| Jun 30, 2021 | 55.22 Mn |
| Jun 30, 2021 | 55.22 Mn |
| Mar 31, 2021 | -19.96 Mn |
| Mar 31, 2021 | -19.96 Mn |
| Dec 31, 2020 | -15.57 Mn |
| Dec 31, 2020 | -15.57 Mn |
| Sep 30, 2020 | -19.48 Mn |
| Sep 30, 2020 | -19.48 Mn |
| Jun 30, 2020 | -14.04 Mn |
| Jun 30, 2020 | -14.04 Mn |
| Mar 31, 2020 | -3.09 Mn |
| Mar 31, 2020 | -3.09 Mn |
| Dec 31, 2019 | -9.65 Mn |
| Dec 31, 2019 | -9.65 Mn |
| Sep 30, 2019 | -14.64 Mn |
| Sep 30, 2019 | -14.64 Mn |
| Jun 30, 2019 | -16.65 Mn |
| Jun 30, 2019 | -16.65 Mn |
| Mar 31, 2019 | -569,000.00 |
| Mar 31, 2019 | -569,000.00 |
| Dec 31, 2018 | 11.64 Mn |
| Dec 31, 2018 | 11.64 Mn |
| Sep 30, 2018 | -20.08 Mn |
| Sep 30, 2018 | -20.08 Mn |
| Jun 30, 2018 | -26.99 Mn |
| Jun 30, 2018 | -26.99 Mn |
| Mar 31, 2018 | -23.39 Mn |
| Mar 31, 2018 | -23.39 Mn |
| Dec 31, 2017 | -19.72 Mn |
| Dec 31, 2017 | -19.72 Mn |
| Sep 30, 2017 | -17.61 Mn |
| Sep 30, 2017 | -17.61 Mn |
| Jun 30, 2017 | -19.47 Mn |
| Jun 30, 2017 | -19.47 Mn |
| Mar 31, 2017 | -20.76 Mn |
| Mar 31, 2017 | -20.76 Mn |
| Dec 31, 2016 | -12.46 Mn |
| Dec 31, 2016 | -12.46 Mn |
| Sep 30, 2016 | -22.57 Mn |
| Sep 30, 2016 | -22.57 Mn |
| Jun 30, 2016 | -18.43 Mn |
| Jun 30, 2016 | -18.43 Mn |
| Mar 31, 2016 | -22.42 Mn |
| Mar 31, 2016 | -22.42 Mn |
| Dec 31, 2015 | -13.80 Mn |
| Dec 31, 2015 | -13.80 Mn |
| Sep 30, 2015 | -9.46 Mn |
| Sep 30, 2015 | -9.46 Mn |
| Jun 30, 2015 | -18.15 Mn |
| Jun 30, 2015 | -18.15 Mn |
| Mar 31, 2015 | 17.99 Mn |
| Mar 31, 2015 | 17.99 Mn |
| Dec 31, 2014 | -15.00 Mn |
| Dec 31, 2014 | -15.00 Mn |
| Sep 30, 2014 | -18.38 Mn |
| Sep 30, 2014 | -18.38 Mn |
| Jun 30, 2014 | -19.94 Mn |
| Jun 30, 2014 | -19.94 Mn |
| Mar 31, 2014 | -16.43 Mn |
| Mar 31, 2014 | -16.43 Mn |
| Dec 31, 2013 | -18.90 Mn |
| Dec 31, 2013 | -18.90 Mn |
| Sep 30, 2013 | -20.74 Mn |
| Sep 30, 2013 | -20.74 Mn |
| Jun 30, 2013 | -21.32 Mn |
| Jun 30, 2013 | -21.32 Mn |
| Mar 31, 2013 | -25.11 Mn |
| Mar 31, 2013 | -25.11 Mn |
| Dec 31, 2012 | -21.57 Mn |
| Dec 31, 2012 | -21.57 Mn |
| Sep 30, 2012 | -19.63 Mn |
| Sep 30, 2012 | -19.63 Mn |
| Jun 30, 2012 | -20.74 Mn |
| Jun 30, 2012 | -20.74 Mn |
| Mar 31, 2012 | -23.27 Mn |
| Mar 31, 2012 | -23.27 Mn |
| Dec 31, 2011 | -18.65 Mn |
| Dec 31, 2011 | -18.65 Mn |
| Sep 30, 2011 | -12.79 Mn |
| Sep 30, 2011 | -12.79 Mn |
| Jun 30, 2011 | -17.17 Mn |
| Jun 30, 2011 | -17.17 Mn |
| Mar 31, 2011 | -20.76 Mn |
| Mar 31, 2011 | -20.76 Mn |
| Dec 31, 2010 | 10.27 Mn |
| Dec 31, 2010 | 10.27 Mn |
| Sep 30, 2010 | -19.01 Mn |
| Sep 30, 2010 | -19.01 Mn |